GAMMA Investing LLC Has $145.37 Million Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

GAMMA Investing LLC grew its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 56,237.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 91,267 shares of the company's stock after buying an additional 91,105 shares during the period. GAMMA Investing LLC owned 0.31% of Inspire Medical Systems worth $145,370,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of INSP. First Horizon Advisors Inc. increased its holdings in shares of Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock valued at $26,000 after acquiring an additional 124 shares in the last quarter. Huntington National Bank grew its stake in shares of Inspire Medical Systems by 228.3% during the 4th quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after purchasing an additional 121 shares during the period. True Wealth Design LLC raised its position in shares of Inspire Medical Systems by 39.0% in the fourth quarter. True Wealth Design LLC now owns 196 shares of the company's stock worth $36,000 after acquiring an additional 55 shares during the period. Harbour Investments Inc. increased its position in shares of Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after buying an additional 99 shares in the last quarter. Finally, AlphaQuest LLC raised its position in Inspire Medical Systems by 7,275.0% during the fourth quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after acquiring an additional 291 shares during the period. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Buying and Selling at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 360 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the completion of the sale, the director now directly owns 24,046 shares in the company, valued at approximately $3,847,360. This trade represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.

Inspire Medical Systems Stock Performance

Shares of Inspire Medical Systems stock traded up $1.64 on Thursday, reaching $139.55. The stock had a trading volume of 93,060 shares, compared to its average volume of 560,456. The business's 50-day moving average price is $150.02 and its two-hundred day moving average price is $172.39. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $225.00. The stock has a market cap of $4.12 billion, a P/E ratio of 80.51, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.33. The firm had revenue of $201.32 million during the quarter, compared to analysts' expectations of $194.89 million. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The company's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.34) earnings per share. As a group, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSP has been the topic of several analyst reports. Robert W. Baird lifted their price target on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a report on Tuesday, May 6th. Morgan Stanley cut their price target on shares of Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. KeyCorp decreased their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Finally, Piper Sandler cut their price target on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Inspire Medical Systems has an average rating of "Moderate Buy" and an average target price of $211.91.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.